Study Identifies Key Enzyme That Could Be Targeted to Fight Brain Cancers

Researchers at Ohio State University Medical Center have identified a key enzyme that may be used to combat one of the deadliest types of brain cancer. Known as PGM3, this enzyme plays a critical role in the hexosamine biosynthesis pathway, which contributes to rapid tumor growth through protein and lipid glycosylation. Targeting PGM3 could significantly improve glioblastoma treatment outcomes.

Glioblastomas are highly malignant tumors that typically form in the brain or spinal cord. They spread rapidly from their onset, causing increased intracranial pressure and symptoms such as headaches, nausea, drowsiness, blurred vision, seizures, and personality changes. These tumors are particularly aggressive and often resistant to conventional treatments like chemotherapy and radiation, making glioblastoma one of the deadliest forms of brain cancer.

Researchers from the Ohio State University (OSU) Comprehensive Cancer Center – Arthur G. James & Richard J. Solove Research Institute identified PGM3 as a promising therapeutic target. Their findings suggest that inhibiting this enzyme disrupts a critical link between fat and sugar production in cancer cells, halting the tumor’s aggressive growth.

Lead study author who is the Center for Cancer Metabolism director, Dr. Deliang Guo, noted that PGM3 inhibition could pave the way for more effective glioblastoma therapies. According to the Glioblastoma Foundation, around 15,000 individuals receive glioblastoma diagnoses annually. The condition has a grim prognosis: the average survival time is approximately 8 months, and only 6.9% of patients survive beyond five years post-diagnosis.

Given the extremely poor survival rate, glioblastoma remains one of the most fatal brain cancers globally, and researchers are continually seeking more effective treatments. Guo emphasized that the discovery opens new avenues for glioblastoma research and therapeutic development.

Dr. Huali Su, the study’s first author and a researcher in the Department of Radiation Oncology at OSUCCC–James Center for Cancer Metabolism, stated that glioblastoma is the most lethal primary brain tumor, with a median survival time of only 12 to 16 months, even with intensive treatment. As a result, Su emphasized the urgent need for novel molecular targets that can enhance the effectiveness of existing therapies.

This breakthrough in glioblastoma research could lead to the development of targeted treatments that significantly improve survival outcomes for patients battling one of the most aggressive forms of brain cancer. The research was a collaborative effort involving scientists from France, as well as the University of Louisville, the University of California–Irvine, and the University of California–Los Angeles.

Various enterprises like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) focused on brain cancer treatment development are also making progress in their drug development efforts. A time is coming when glioblastomas and other brain cancers will be treated as effectively as other malignancies.

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office